Versions
- 2024-08-02 (2)
- 2024-08-02 (1)
Keywords
Human Papillomavirus
health policy
Abstract
Abstract
Introduction: Cervical cancer is a global health concern primarily caused by human papillomavirus (HPV). It has a significant impact in Germany, with thousands of new diagnoses and deaths annually. Despite advancements in screening and treatment leading to improved survival rates of 65% for invasive cervical tumors, the financial burden remains substantial.
Aims: The study aims to assess the impact of gender and education of Wiesbaden students towards cervical cancer and its associated health policies. Data was collected through an online questionnaire distributed with 54 students in Wiesbaden, Germany participating in the study. Statistical analysis was performed using SPSS, including one-way ANOVA, t-tests, Kruskal-Wallis, and chi-square tests. The respondents' average age was 28.24 years, with a higher female participation.
Results: Education level did not significantly influence perceptions of ideal vaccination age (p<0.581). Females and males perceived a lower number of vaccine doses (<3) required compared to the standard. Education level showed a moderate association with knowledge of long-term complications, and gender had a moderate correlation with information sources (rho=27, p=0.090).
Conclusion: Gender disparities did not significantly impact knowledge of cervical cancer. Public health programs should consider education levels and tailor interventions to all age groups and genders.
References
K. S. Okunade, “Human papillomavirus and cervical cancer,” J. Obstet. Gynaecol., vol. 40, no. 5, pp. 602–608, 2020, doi: 10.1080/01443615.2019.1634030.
A. Robadi, M. Pharaon, and B. S. Ducatman, “The Importance of High-Risk Human Papillomavirus Types Other Than 16 and 18 in Cervical Neoplasia,” Arch. Pathol. Lab. Med., vol. 142, no. 6, pp. 693–695, 2018, doi: 10.5858/arpa.2017-0563-ra.
M. Sindiani, E. H. Alshdaifat, and A. J. Alkhatib, “Investigating Cervical Risk Factors that Lead to Cytological and Biopsy Examination,” Méd. Arch., vol. 74, no. 4, pp. 294–297, 2020, doi: 10.5455/medarh.2020.74.294-297.
P. A. Cohen, A. Jhingran, A. Oaknin, and L. Denny, “Cervical cancer,” Lancet, vol. 393, no. 10167, pp. 169–182, 2019, doi: 10.1016/s0140-6736(18)32470-x.
M. H. Chung et al., “Comparing Papanicolau smear, visual inspection with acetic acid and human papillomavirus cervical cancer screening methods among HIV-positive women by immune status and antiretroviral therapy,” AIDS, vol. 27, no. 18, pp. 2909–2919, 2013, doi: 10.1097/01.aids.0000432472.92120.1b.
G. Sroczynski et al., “Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany,” GMS Heal. Technol. Assess., vol. 6, p. Doc05, doi: 10.3205/hta000083.
S. Kamolratanakul and P. Pitisuttithum, “Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer,” Vaccines, vol. 9, no. 12, p. 1413, 2021, doi: 10.3390/vaccines9121413.
Z. Hu and D. Ma, “The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications,” Cancer Med., vol. 7, no. 10, pp. 5217–5236, 2018, doi: 10.1002/cam4.1501.
M. Jentschke, R. Lehmann, N. Drews, A. Hansel, M. Schmitz, and P. Hillemanns, “Psychological distress in cervical cancer screening: results from a German online survey,” Arch. Gynecol. Obstet., vol. 302, no. 3, pp. 699–705, 2020, doi: 10.1007/s00404-020-05661-9.
“Krebs - Cervical cancer.” https://www.krebsdaten.de/Krebs/EN/Content/Cancer_sites/Cervical_cancer/cervical_cancer_node.html (accessed Aug. 22, 2022).
S. F. Armstrong and J. F. Guest, “Cost-Effectiveness and Cost-Benefit of Cervical Cancer Screening with Liquid Based Cytology Compared with Conventional Cytology in Germany,” Clin. Outcomes Res.: CEOR, vol. 12, pp. 153–166, 2020, doi: 10.2147/ceor.s234385.
F. Harlow, A. Zheng, J. Nordberg, E. E. Hatch, S. Ransbotham, and L. A. Wise, “A qualitative study of factors influencing male participation in fertility research,” Reprod. Heal., vol. 17, no. 1, p. 186, 2020, doi: 10.1186/s12978-020-01046-y.
S. Hense, K. Hillebrand, J. Horn, R. Mikolajczyk, R. Schulze-Rath, and E. Garbe, “HPV vaccine uptake after introduction of the vaccine in Germany,” Hum. Vaccines Immunother., vol. 10, no. 6, pp. 1729–1733, 2014, doi: 10.4161/hv.28450.